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Summary
 
A panel of cDNAs encoding allergenic proteins was isolated from an 
 
Aspergillus fumigatus
 
cDNA library displayed on the surface of filamentous phage. Solid phase–immobilized serum
immunoglobulin E (IgE) from 
 
A
 
.
 
 fumigatus
 
–allergic individuals was used to enrich phage dis-
playing IgE-binding molecules. One of the cDNAs encoded a 11.1-kD protein that was iden-
tified as acidic ribosomal phosphoprotein type 2 (P
 
2
 
 protein). The allergen, formally termed
rAsp f 8, shares 
 
.
 
62% sequence identity and 
 
.
 
84% sequence homology to corresponding eu-
karyotic P
 
2
 
 proteins, including human P
 
2
 
 protein. The sequences encoding human and fungal
P
 
2
 
 protein were subcloned, expressed in 
 
Escherichia coli
 
 as His
 
6
 
-tagged fusion proteins, and pu-
rified by Ni
 
2
 
1
 
–chelate affinity chromatography. Both recombinant P
 
2
 
 proteins were recognized
by IgE antibodies from allergic individuals sensitized to the 
 
A
 
.
 
 fumigatus
 
 P
 
2
 
 protein and elicited
strong type 1–specific skin reactions in these individuals. Moreover, human and fungal P
 
2
 
 pro-
teins induced proliferative responses in peripheral blood mononuclear cells of 
 
A
 
.
 
 fumigatus
 
–
allergic subjects sensitized to the fungal P
 
2
 
 protein. These data provide strong evidence for in
vitro and in vivo humoral and cell-mediated autoreactivity to human P
 
2
 
 protein in patients suf-
fering from chronic 
 
A
 
.
 
 fumigatus
 
 allergy.
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A
 
spergillus fumigatus
 
, a ubiquitous mold (1), is considered
an opportunistic pathogen responsible for a vast variety
of pulmonary complications in humans and animals. The
spectrum of diseases associated with the fungus ranges from
mild forms, like saprophytic colonization of the lung and
allergy, to life-threatening diseases, such as invasive sys-
temic aspergillosis or allergic bronchopulmonary aspergillo-
sis (ABPA) (2). These different clinical presentations indi-
cate that not only the virulence of the fungus itself, but also
other underlying conditions, including impaired immune
status, play a role in the development of opportunistic my-
coses (3). Cloning and sequencing of allergen-encoding
cDNAs from 
 
A
 
.
 
 fumigatus
 
 (4–6) have permitted character-
ization of the biochemical function of some allergens by se-
quence comparison. The 18-kD protein Asp f 1, a member
of the ribotoxin family (4, 7), represents a major allergen of
the fungus (7, 8) and was found in the urine of patients
with invasive aspergillosis (9). Serologic studies with rAsp f 1
and other 
 
A
 
.
 
 fumigatus
 
 allergens (10) clearly demonstrated
the existence of disease-specific allergens able to elicit IgE
responses exclusively in patients suffering from ABPA (10–
12). Although the pathophysiologic mechanisms leading to
 
Aspergillus
 
-related pulmonary complications remain largely
unknown, the availability of recombinant allergens from
the fungus substantially contributed to improved diagnosis
of the diseases (11–14). At the molecular level, the cloned
allergens can be subdivided into two categories: secreted
and cytoplasmatic proteins (10). Interestingly, at least one
of the ABPA-specific allergens, manganese-dependent super-
oxide dismutase (MnSOD), a phylogenetically highly con-
served protein (15), also shows cross-reactivity with human
MnSOD (16). Phylogenetically conserved proteins are of-
ten involved in fungal allergy (17) and also have the poten-
tial to be involved in humoral and cell-mediated autoim-
mune reactions (15, 18). We have cloned a large panel of
cDNAs encoding allergenic 
 
A
 
.
 
 fumigatus
 
 proteins using
phage surface display technology (5, 6, 19). Here, we de-
scribe the sequence and properties of one of these allergens
identified as an 
 
A
 
.
 
 fumigatus
 
 acidic ribosomal phosphopro-
tein type 2 (P
 
2
 
 protein) by sequence homology. The acidic 
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ribosomal phosphoproteins P
 
0
 
 (38 kD), P
 
1
 
 (13 kD), and P
 
2
 
(13 kD), contained in the 60 S ribosomal subunit, are
highly conserved among eukaryotes and are required for
the functional activity of the ribosome (20). These proteins
have been reported as antigens capable of inducing IgG an-
tibody responses in systemic lupus erythematosus, the pro-
totypic systemic autoimmune disease (21, 22). Additionally,
the P
 
2
 
 proteins from 
 
Alternaria alternata
 
 and 
 
Cladosporium
herbarum
 
 have been reported to be minor allergens of these
molds (17). The 
 
A
 
.
 
 fumigatus
 
 P
 
2
 
 protein is recognized by
IgE antibodies of individuals sensitized to the mold and
shows significant humoral cross-reactivity to human P
 
2
 
protein. Both human and 
 
A
 
.
 
 fumigatus
 
 P
 
2
 
 proteins induce
strong type 1 skin reactions and proliferative responses in
PBMCs of individuals sensitized to the fungal P
 
2
 
 protein.
 
Materials and Methods
 
Construction and Screening of an A. fumigatus cDNA Library Dis-
played on Phage Surface.
 
Phage displaying IgE-binding proteins
were enriched from an 
 
A
 
.
 
 fumigatus
 
 cDNA library constructed in
phagemid pJuFo (19) and displayed on the surface of filamentous
phage M13 as described (5, 6). Serum IgE from 
 
A
 
.
 
 fumigatus
 
–sensi-
tized individuals was captured in microtiter plates coated with anti–
human mAb TN 142 and used as ligand for selective enrichment
of allergen-displaying phage (6). Sera used for screening were se-
lected according to case history, skin test reactivity to commercial
 
A
 
.
 
 fumigatus
 
 extracts, and specific IgE to 
 
A
 
.
 
 fumigatus
 
 determined
by radioallergosorbent test (RAST) (8). The screening procedure
yielded a wide variety of phage able to bind specifically to human
serum IgE and thus displaying allergenic molecules (5, 6).
 
Identification of a Clone Encoding A. fumigatus P
 
2
 
 Protein.
 
Inserts
carried by phage displaying IgE-binding proteins differing in
length were sequenced as described (23) on an ABI prism 373A
sequencer using the 
 
d
 
-rhodamine terminator cycle sequencing kit
(Perkin-Elmer) according to the manufacturer’s instructions. Both
DNA strands were sequenced using vector-derived primers. Ho-
mology searches and sequence comparisons were performed with
BLAST and the Genetics Computer Group program FASTA (24).
One clone revealed strong homology with nucleotide sequences
encoding acidic ribosomal phosphoprotein type 2 (see Fig. 1).
 
Cloning of the Human P
 
2
 
 Protein; Production and Characterization
of Recombinant Proteins.
 
The cDNA encoding human P
 
2
 
 protein
was amplified by PCR from a commercial human lung cDNA li-
brary (Stratagene) using the following primers: 5
 
9
 
-primer, 5
 
9
 
-GCG-
GATCCATGCGCTACGTCGCCTCCTACC-3
 
9
 
; 3
 
9
 
-primer,
5
 
9
 
-GCTCTAGATTAATCAAAAAGGCCAAATCCC-3
 
9
 
. The
complete cDNA coding for the putative 
 
A
 
.
 
 fumigatus
 
 P
 
2
 
 protein
was amplified from the original clone by PCR using the follow-
ing primers: 5
 
9
 
-primer, 5
 
9
 
-GCGGATCCATGAAGTACCTC-
GCAGCTTTCC-3
 
9
 
; 3
 
9
 
-primer, 5
 
9
 
-CCCGGACTTTAAGTC-
GAAGAGACCGAAGCCC-3
 
9
 
. PCR cycling conditions were 30
cycles of 95
 
8
 
C for 60 s, 57
 
8
 
C for 60 s, and 72
 
8
 
C for 60 s, followed
by a terminal extension cycle at 72
 
8
 
C for 10 min. The amplifica-
tion products were purified using a commercial kit (QIAquick;
QIAGEN, Inc.), digested with BamHI and XbaI or BamHI and
HindIII, respectively, and ligated to appropriately restricted
pHis
 
6
 
–DHFR (dihydrofolate reductase) vector (4). Ligation mix-
tures were transformed into 
 
Escherichia coli
 
 strain M 15; transfor-
mants were grown in liquid to verify the nucleotide sequence
(23) and used to produce hexahistidine-tagged recombinant pro-
 
teins (4, 6). After a single-step purification over Ni
 
2
 
1
 
–chelate af-
finity columns (6), molecular size and purity of the recombinant
proteins were analyzed by polyacrylamide gradient gels (4.5–20%)
and 1-mg samples lyophilized for long term storage (14).
 
ELISA and IgE Immunoblots.
 
The specific binding properties
of serum IgE from 
 
A
 
.
 
 fumigatus
 
–sensitized individuals to recombi-
nant fungal and human P
 
2
 
 protein were analyzed by an allergen-
specific ELISA (8). Absorbency was measured at 405 nm with a
Molecular Devices reader and optical densities converted into
arbitrary ELISA units (EU/ml) calibrated against an in-house serum
pool arbitrarily defined as 100 EU/ml (8, 11, 12). Values below
1 EU/ml were set as 1 EU/ml for graphic display and nonpara-
metric statistical analysis (Mann–Whitney U test). For IgE immu-
noblots, proteins were separated on SDS–polyacrylamide gradient
gels (4–20%), transferred to nitrocellulose, incubated with patient
sera diluted 1:10, and processed as described (16, 25).
 
Proliferative Responses of PBMCs.
 
PBMCs were isolated from
heparinized peripheral venous blood by Ficoll density gradient
centrifugation, washed three times, and resuspended in RPMI 1640
supplemented with 1 mM sodium pyruvate, 2 mM 
 
l
 
-glutamine, 50
 
m
 
M 2-ME, 1% MEM nonessential amino acids and vitamins, 100
 
m
 
g/ml streptomycin, 100 U/ml penicillin (all from Life Technol-
ogies), and 10% heat-inactivated FCS (Sera-Lab). Samples of 5 
 
3
 
10
 
5 cells/100 ml were stimulated with different concentrations of
recombinant A. fumigatus or human P2 protein or with A. fumigatus
extract in triplicate for 7 d. Proliferation was measured as incorpo-
ration of tritiated thymidine (DuPont-NEN) during the final 16 h
of culture. A stimulation index .3 was considered positive.
Skin Tests with Recombinant P2 Protein. Recombinant proteins
were dissolved in 0.9% saline at concentrations ranging from 1025
to 1 mg/ml. Intradermal skin tests were performed on the patient’s
back by injecting 100 ml test solution containing 1 ng recombi-
nant protein. If no positive reaction could be observed after 15
min, testing was continued by injecting a 10-fold higher amount
of protein. The test was stopped and considered positive when
the wheal surface reached at least half of the histamine wheal size
(8, 16) or after injection of 1 mg protein. 0.01% histamine dihy-
drochloride and 0.9% saline were used as positive and negative
controls, respectively (8). An ethical approval for skin testing hu-
man subjects with recombinant proteins was obtained from the
local ethics committee (Davos, Switzerland). A full explanation of
the procedure was given to all participants, and their written con-
sent was obtained before testing.
Results and Discussion
Isolation of cDNA Clones and Sequence Analysis. The clon-
ing technology based on phage surface display of expression
products from cDNA libraries (5, 6, 19) is particularly suit-
able for selective isolation of cDNAs encoding IgE-binding
proteins from complex allergenic systems (26). Starting
from a phage surface–displayed cDNA library generated
from mRNA of A. fumigatus (6), we selectively enriched
phage able to bind human serum IgE from individuals sen-
sitized to the fungus. cDNAs isolated from single phage-
mids after four rounds of affinity selection, carrying inserts
of different lengths, were sequenced and shown to code for
different allergenic proteins (10). Among these, a clone con-
taining an open reading frame spanning 333 bp (sequence
data available from EMBL under accession no. AJ224333)
revealed strong homology with sequences encoding eukary-1509 Mayer et al. Brief Definitive Report
otic type 2 acidic ribosomal phosphoproteins. The deduced
amino acid sequence of this cDNA clone was homologous
to P2 proteins, showing a high sequence identity to the hu-
man (62%), C. herbarum (71%), and A. alternata (72%) P2 pro-
teins (Fig. 1). Acidic ribosomal phosphorylated (P) proteins
have been isolated and characterized from a variety of eu-
karyotic cells and share significant sequence identity and
similarity (20).
Production and Characterization of Recombinant A. fumigatus
and Human P2 Proteins.  Both complete cDNAs encoding
the putative A. fumigatus P2 protein and the human P2 pro-
tein were amplified by PCR, subcloned into the high level
expression plasmid pHis6–DHFR, verified by sequencing,
and used to produce hexahistidine-tagged P2 proteins (see
Materials and Methods). The constructs yielded, after single-
step purification by Ni21–chelate affinity chromatography,
33 and 28 mg/liter E. coli culture of virtually pure A. fumi-
gatus and human P2 protein, respectively. Purity was ana-
lyzed by reducing, denaturing SDS-PAGE, and Coomassie
blue staining. In each preparation, only one band with esti-
mated molecular mass in agreement with the calculated
values of z12.6 kD for the hexahistidine-tagged A. fumiga-
tus and human P2 protein was visible (data not shown).
Allergenic Properties of the P2 Proteins. As expected from
the selection procedure devoted to isolate allergens from a
phage surface display library, the A. fumigatus P 2 protein
was able to bind IgE present in the serum used for screen-
ing. However, both A. fumigatus and human P2 proteins
were identified as allergens by ELISA with sera from indi-
viduals allergic to A. fumigatus (Fig. 2) and by IgE immuno-
blots (data not shown). Inhibition experiments showed that
increasing amounts of human recombinant P2 protein
added to the fluid phase were able to inhibit the binding of
serum IgE from patients sensitized to A. fumigatus P2 pro-
tein (Fig. 3), demonstrating that the proteins share com-
mon IgE-binding epitopes. 14/92 patients studied that
were suffering from ABPA and 6/75 patients that were
allergic to A. fumigatus and suffering from severe atopic
dermatitis studied showed relevant levels of serum IgE anti-
bodies to the A. fumigatus P2 protein, resulting in an in-
cidence of sensitization in the range of 15 and 8%, re-
spectively. Sensitization to P2 protein was not observed in
A. fumigatus–sensitized individuals with mild forms of
atopic dermatitis or in patients without ABPA.
Proliferative Responses of PBMC from Individuals Sensitized
to A. fumigatus P2 Protein. T cell help is required for the
production of allergen-specific IgE (27). Therefore, we
measured the proliferative responses of mononuclear cells
from six individuals sensitized to the A. fumigatus P2 protein
to fungal extract, recombinant A. fumigatus, and human P2
protein. The mean proliferative responses to optimal con-
centrations of extract, fungal, and human P2 protein were
39,500; 20,092; and 11,790 cpm, respectively (mean SI
11.9, 6.5, and 5.7). The mean proliferative responses of
15,608; 1,601; and 1,273 cpm (mean SI 12.6, 0.8, and 1) to
fungal extract, A. fumigatus, and human P2 protein, respec-
tively, obtained for four individuals sensitized to A. fumiga-
tus lacking IgE antibodies against the fungal P2 protein in-
dicate that the recombinant antigens did not induce
nonspecific effects. Three control individuals did not re-
spond to any of the antigen preparations (mean SI , 1).
Comparison of the values by the rank sum test indicates
highly significant differences (P , 0.01). The proliferative
Figure 1. Alignment of the deduced amino acid sequences A. fumigatus
(A. fum), A. alternata (A. alt), C. herbarum (C. her), and human (H. sap) P2
protein sequences. Identical amino acid residues in at least three of the se-
quences are noted by shading, and gaps are indicated by dots. Sequence
identity between A. fumigatus, human, C. herbarum, and A. alternata P 2
proteins are 62.16, 72.07, and 71.17%, respectively. Numbers after the se-
quences indicate the residue numbers, without gaps, starting at the NH2-
terminal methionine residues.
Figure 2. Competitive inhibition of IgE binding to solid phase–coated
A. fumigatus recombinant P2 protein. Serum from A. fumigatus–sensitized
patients was preincubated with increasing amounts of recombinant A. fumi-
gatus (s), human P2 protein (d), or Asp f 1 as negative control (h). Prein-
cubated serum samples were transferred to wells coated with A. fumigatus P2
protein, and bound IgE was analyzed by antigen-specific ELISA (8, 16).
Figure 3. 20 sera from individuals sensitized to (j) and 20 sera of indi-
viduals lacking IgE to the A. fumigatus P2 protein (s) were analyzed for
their content of serum IgE able to recognize human P2 protein (A). (B)
IgE binding of the same sera to A. fumigatus P2 protein is shown. Units are
expressed as arbitrary ELISA units (EU/ml) calculated from the absor-
bency of an in-house reference serum pool, which was set as 100 EU/ml
(8). Bars, mean values.1510 Autoimmunity in Allergy
responses induced by human P2 protein in individuals sen-
sitized to the A. fumigatus P2 protein indicate a pathogenesis
related to autoreactive T cells. Intense local inflammatory
responses to A. fumigatus occurring in the lungs of patients
suffering from ABPA (11, 12) and in the skin of patients
suffering from severe atopic dermatitis might result in re-
lease of autoantigens as a consequence of tissue damage due
to the inflammatory process (28). Exposure to autoantigens
containing cross-reactive determinants (molecular mimicry)
can recruit the memory T cell repertoire at the site of in-
flammation where lymphokine expression is upregulated.
These lymphokines can induce expression of MHC II on
naive T cells and upregulate accessory molecules that func-
tion as costimulatory signals for T cell activation, creating a
microenvironment in which all requirements for priming a
T cell response are present (29). Molecular mimicry at the
T cell level could be a possible pathogenic mechanism to
explain autoaggression remaining confined to the local area
of inflammation (29).
Allergenicity of the Recombinant P2 Proteins In Vivo. The
ability of a protein to bind IgE in ELISA and Western blots
provides strong evidence for the allergenicity of the pro-
tein. However, the final demonstration that a protein prep-
aration acts as an allergen and therefore possesses biological
activity in vivo is its ability to elicit a type I skin reaction in
sensitized individuals. We have investigated whether the
IgE-mediated cross-reactivity against A. fumigatus and hu-
man P2 protein shown in vitro is sufficient to provoke al-
lergic reactions in vivo through skin tests (8, 16). Four in-
dividuals with high IgE levels against A. fumigatus P 2
protein, four individuals allergic to the fungus lacking IgE
responses to the P2 protein, and two nonallergic control in-
dividuals were investigated for their ability to respond to
intradermal challenge with recombinant A. fumigatus and
human P2 proteins. As expected, none of the individuals
without detectable IgE antibodies to A. fumigatus P2 protein
reacted against the recombinant protein preparations. A
positive skin reaction to A. fumigatus P 2 protein was de-
tected only in individuals who had IgE levels .10 EU/ml
to the fungal protein. The amounts of recombinant protein
needed to elicit a classical type I reaction ranged from 1 to
10 ng, depending on the subject. All individuals reacting to
A. fumigatus P2 protein also showed strong skin reaction
to challenges with comparable amounts of human P2 protein
(Fig. 4). These results show that human P2 protein can
cross-link IgE on mast cells in vivo (30) and suggest hu-
moral autoimmune response in some patients suffering
from mold allergy. IgE reactivity to fungal and human P2
protein was, however, only detectable in individuals sensi-
tized to A. fumigatus suffering from ABPA or severe atopic
dermatitis. This was also the case for the IgE autoreactivity
to human MnSOD described earlier (16). Therefore, these
two human proteins may serve as a tool to study the role of
IgE autoreactivity in tissue damage and release of autoanti-
gens at the site of inflammation.
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Figure 4. Skin test reactivity to recombinant A. fumigatus and human
proteins in a patient sensitized to MnSOD and P2 protein. For intrader-
mal skin tests, 100 ml of the protein solutions (1021 mg/ml) was injected
with a syringe. 0.01% histamine dihydrochloride (A) and 0.9% saline (B)
were used as positive and negative controls, respectively. The reactions
show that 10 ng fungal (D) and human (E) P2 protein or fungal (H) and
human (I) MnSOD are able to elicit a wheal that is comparable to the size
of the skin reaction induced by the positive histamine control. C shows
the reaction to a challenge with 1 ng human P2 protein. The patient lacks
IgE to rAsp f 3 (F) and rAsp f 11 (G), two additional A. fumigatus allergens
(10). The absence of reactions to skin challenges with these allergens
demonstrates the specificity of the test.1511 Mayer et al. Brief Definitive Report
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